<?xml version='1.0' encoding='utf-8'?>
<document id="18548209"><sentence text="[Echinocandins in invasive candidiasis]." /><sentence text="Invasive fungal infections on the intensive care unit are predominantly caused by Candida spp" /><sentence text=", most frequently manifesting as candidemia" /><sentence text=" In spite of increasing treatment options during the last 2 decades, mortality of invasive candidiasis remains high with 20-50%" /><sentence text=" With the echinocandins, a new class of antifungal drugs with activity against clinically relevant Aspergillus and Candida spp" /><sentence text=" has become available since the beginning of the new millennium"><entity charOffset="53-63" id="DDI-PubMed.18548209.s6.e0" text="millennium" /></sentence><sentence text=" The echinocandins have shown convincing efficacy in numerous multicenter, mostly double-blinded phase III clinical trials"><entity charOffset="5-18" id="DDI-PubMed.18548209.s7.e0" text="echinocandins" /></sentence><sentence text=" These trials compared current standard treatment regimens with the echinocandins anidulafungin, caspofungin, and micafungin"><entity charOffset="97-108" id="DDI-PubMed.18548209.s8.e0" text="caspofungin" /><entity charOffset="114-124" id="DDI-PubMed.18548209.s8.e1" text="micafungin" /><pair ddi="false" e1="DDI-PubMed.18548209.s8.e0" e2="DDI-PubMed.18548209.s8.e0" /><pair ddi="false" e1="DDI-PubMed.18548209.s8.e0" e2="DDI-PubMed.18548209.s8.e1" /></sentence><sentence text=" All trials observed noninferiority of the new drugs against the standard treatment; in the case of anidulafungin, superiority against fluconazole was demonstrated"><entity charOffset="100-113" id="DDI-PubMed.18548209.s9.e0" text="anidulafungin" /><entity charOffset="135-146" id="DDI-PubMed.18548209.s9.e1" text="fluconazole" /><pair ddi="false" e1="DDI-PubMed.18548209.s9.e0" e2="DDI-PubMed.18548209.s9.e0" /><pair ddi="false" e1="DDI-PubMed.18548209.s9.e0" e2="DDI-PubMed.18548209.s9.e1" /></sentence><sentence text=" Especially in trials utilizing amphotericin B as comparator, significantly less treatment-related adverse events were observed when using an echinocandin"><entity charOffset="32-46" id="DDI-PubMed.18548209.s10.e0" text="amphotericin B" /><entity charOffset="142-154" id="DDI-PubMed.18548209.s10.e1" text="echinocandin" /><pair ddi="false" e1="DDI-PubMed.18548209.s10.e0" e2="DDI-PubMed.18548209.s10.e0" /><pair ddi="true" e1="DDI-PubMed.18548209.s10.e0" e2="DDI-PubMed.18548209.s10.e1" /></sentence><sentence text=" Echinocandins have a low drug-drug interaction profile and are only marginally affected by liver function"><entity charOffset="1-14" id="DDI-PubMed.18548209.s11.e0" text="Echinocandins" /></sentence><sentence text=" Especially in ICU (intensive care unit) patients frequently showing single- or multiorgan failure and receiving a multitude of drugs with complex interactions, echinocandins have become the treatment of first choice for invasive candidiasis" /><sentence text="" /></document>